Latest news with #dataaccess
Yahoo
4 days ago
- Business
- Yahoo
Clarivate and CAPES Expand Landmark Partnership to Power Research and Innovation Across Brazil
New five-year agreement delivers critical academic and life sciences insights into more than 400 institutions, broadening access and driving national research excellence LONDON, June 2, 2025 /CNW/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today announced the renewal of its multi-year partnership with CAPES (Coordenação de Aperfeiçoamento de Pessoal de Nível Superior), significantly expanding access to trusted Academia & Government and Life Sciences & Healthcare data across over 400 Brazilian institutions. As compared to the previous contract, the agreement increases institutional coverage by 57%, extending the reach of high-quality research tools to universities and research centers across Brazil — from major metropolitan areas to the country's most remote regions. As a key agency under Brazil's Ministry of Education, CAPES plays a vital role in advancing postgraduate education, supporting high-level training, and fostering international scientific collaboration. A long-standing partner to CAPES, Clarivate began its collaboration with the agency in 2001, when the Web of Science became one of the first databases integrated into the CAPES Portal. This new agreement builds on that legacy, delivering enhanced access to solutions including Web of Science, Journal Citation Reports, Cortellis Drug Discovery Intelligence and Derwent Innovation Index. By bringing together world-class data and insights from academic research and the life sciences and healthcare sectors, the agreement empowers researchers and practitioners at all levels — including scholars, policy advisors, biomedical scientists and healthcare professionals — to conduct innovative research, develop new treatments, improve patient care, and inform policy decisions. It provides broad access to critical information, advancing evidence-based discovery, education and decision-making across disciplines. Matti Shem Tov, Chief Executive Officer, Clarivate, said: "This expanded partnership with CAPES is a powerful example of how strategic collaboration can accelerate research and innovation on a national scale. Brazil has made remarkable progress in advancing scientific excellence and global collaboration. We're proud to support this momentum by providing trusted data, insights, and technology to researchers across the country — from early discovery through impact assessment. Our shared commitment to expanding access and fostering innovation will continue to shape the future of research in Brazil and beyond." Denise Pires de Carvalho, President, CAPES, said: "Brazil is experiencing a moment of growing scientific output beyond its major urban centers, with resources now being distributed in a more equitable and democratic way to boost productivity across all regions. This collaboration with Clarivate enables us to better understand the scientific production profile of Brazilian institutions and supports more informed investment decisions to reduce regional disparities, which remains a significant national challenge. Many researchers in the North, Northeast and Center-West have limited access to the resources needed to give visibility to their work and expanding that access can make a meaningful difference." The renewed partnership reflects a shared commitment to democratizing access to critical scientific information and enabling data-driven research excellence. Through Web of Science, Journal Citation Reports, and Derwent Innovation Index, academic institutions and government agencies gain deeper visibility into global research trends, publication impact, and innovation pathways — supporting policy development, institutional benchmarking, and scholarly advancement. Complementing these capabilities, expanded access to Cortellis Drug Discovery Intelligence equips Brazil's life sciences community — including postgraduate students, faculty, and biomedical researchers — with comprehensive insights across biology, pharmacology, and chemistry. From disease understanding and drug interactions to clinical studies and intellectual property, users can more efficiently navigate the full R&D lifecycle and accelerate decision-making in high-impact research areas. By significantly expanding access to trusted research and innovation tools, this agreement supports CAPES' mission to reduce regional disparities and foster inclusive academic excellence. Institutions from across Brazil — from leading urban universities to those in underserved and remote regions — can now leverage high-quality data to strengthen postgraduate programs, accelerate innovation, and elevate the global visibility of Brazilian research. Clarivate values its collaboration with CAPES on this initiative to help shape a more connected, informed and future-ready research ecosystem across Brazil, and stands as a resource for academic consortia worldwide seeking to expand access to trusted research, data and insights. To learn more about this partnership and the solutions now available to CAPES institutions, visit here. Notes to editors According to the most recent Institute for Scientific Information G20 research and innovation scorecard: Around 40% of Brazilian research output is internationally collaborative, with many strong bilateral partnerships with the United States. It also participates in larger collaborations involving the U.S., the U.K., Spain, Germany, and France. Compared with other internationally collaborative output, these partnerships are producing papers with above average impact. Its research output shows a strong focus on Sustainable Development Goals (SDGs) Zero Hunger (SDG 2) and Life on Land (SDG 15), with impact for both around 0.7 to 0.8 times the world average. More broadly, Brazilian research output has a strong focus on the Life Sciences, while its output in Medicine has impact around 1.1 times the world average. Around 40% of output is published in open access (OA) journals, with their Humanities and Languages output 2.4 times more likely to be published in an OA journal than the G20 average. About ClarivateClarivate is a leading global provider of transformative intelligence. We offer enriched data, insights & analytics, workflow solutions and expert services in the areas of Academia & Government, Intellectual Property and Life Sciences & Healthcare. For more information, please visit About Fundação Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) Fundação Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) is a consortium dedicated to expanding and strengthening postgraduate studies in Brazil. It ensures the quality of academic programs while fostering the development of highly qualified professionals in research, teaching, and other strategic scientific fields. Media contacts: Clarivate Rebecca KrahenbuhlSenior Manager, External Communications – Academia & Governmentnewsroom@ Catherine DanielDirector, External Communications – Life Sciences & Healthcarenewsroom@ CAPESJoão Mendes Communications View original content to download multimedia: SOURCE Clarivate Plc View original content to download multimedia:
Washington Post
28-05-2025
- Business
- Washington Post
DOGE employees may access sensitive Treasury data, judge rules
A federal judge in New York cleared a path Tuesday for the Treasury Department's DOGE team to access data systems that contain sensitive financial information on millions of Americans, stating in her ruling that the Trump administration had complied with earlier requests to demonstrate it is equipped to properly screen and train employees before granting them access. U.S. District Judge Jeannette A. Vargas's ruling allows four U.S. DOGE Service employees at the Treasury Department to access the infrastructure, and opens a path for other employees of Elon Musk's DOGE team to be granted access without judicial approval so long as they undergo training and vetting procedures. 'There is little utility in having this Court function as Treasury's de facto human resources officer each time a new team member is onboarded,' Vargas wrote in court documents filed Tuesday. In February, a coalition of 19 state attorneys general sued the Trump administration over DOGE's activities at Treasury. A federal judge issued an emergency order prohibiting DOGE employees from accessing the data, noting the possibility for irreparable harm. (Treasury's payment system is known to contain social security numbers, home addresses and bank account information.) Later that month, Vargas upheld the ban, stating that there was a public interest in protecting personal and banking information housed at the department's Bureau of Fiscal Service, where systems are generally only used by a small number of civil servants. She gave the Trump administration a chance to alleviate her concerns by providing evidence of efforts to safeguard that data by March 24. She asked for details on what training DOGE members at Treasury have or will have on handling sensitive data; what security clearances they have or will receive; as well as a rundown of the chain of command for DOGE employees assigned to the department. 'Taking the time to adequately mitigate potential security concerns and properly onboard members to engage in this work outweighs the Defendants' immediate need to access and redevelop Treasury systems,' Vargas wrote at the time. In April, Vargas modified her order to grant access to a single DOGE staffer at Treasury who received the same vetting and training as other Treasury employees. On Tuesday, she granted access to three more DOGE employees, stating that they had undergone similar processes and mitigation procedures. DOGE — which stands for the Department of Government Efficiency — has faced several lawsuits over its attempts to access sensitive and classified records at various government agencies, as well as over Musk's unprecedented influence in the government as a temporary employee of the White House who has not been confirmed or vetted by Congress. DOGE employees have either accessed or shown interest in sensitive data systems at the IRS, the Social Security Administration and the Department of Health and Human Services. DOGE representatives have also sought access to a powerful database of nearly all U.S. workers' earnings kept by the health department's child support office, The Washington Post reported in March. Shayna Jacobs contributed to this report.
Forbes
14-05-2025
- Health
- Forbes
OMNY Health Is Healthcare AI For Millions, Not Just Millionaires
Inside the capital-efficient startup using real-world patient data to train AI tools for healthcare access, equity, and impact OMNY Health Founder & CEO Mitesh Rao, MD OMNY Health While Silicon Valley pours billions into longevity tech and concierge medicine for the ultra-wealthy, OMNY Health is building something far more radical: a data infrastructure that can actually improve healthcare for everyone. The Atlanta-based healthcare AI startup is tackling real-world challenges like chronic disease, hospital readmissions, and clinical trial diversity—issues that affect millions of Americans, not just the privileged few. By democratizing access to rich, representative clinical data, OMNY empowers the next wave of healthcare AI solutions to scale across the system, from safety-net hospitals to nationwide research initiatives. Its platform gives health tech developers access to more than 85 million patient records, including over 4 billion unstructured clinical notes, offering a level of depth and breadth that was previously out of reach for most startups. We're at an inflection point in healthcare. Artificial intelligence is advancing rapidly, but the data it feeds on remains fractured, shallow, and unevenly representative. Despite billions poured into AI tools for diagnostics, documentation, and drug discovery, most models still fail to generalize outside controlled test environments. According to a recent Optum survey, 41% of healthcare executives say "data readiness" is the single biggest barrier to scaling AI. In other words, AI isn't stuck because of a lack of ideas—it's stuck because the inputs are broken. That's the challenge OMNY Health is taking on. Last week, it announced the addition of more than 300 clinical assessment measures to its data platform, spanning 10 medical specialties—from neurology and gastroenterology to autoimmune disease and cardiology. These validated indices track everything from disease progression to treatment response, filling in the blind spots that plague traditional claims datasets and specialty registries. 'Our network of more than 85 million patients represents every diverse aspect of the American healthcare experience,' said Dr. Mitesh Rao, CEO and co-founder of OMNY Health. 'OMNY's real-world data will now be the deepest and most comprehensive source of clinical information for the nation.' The OMNY Health platform OMNYHealth Dr. Rao added, 'As an emergency medicine physician and health services researcher, I saw firsthand how siloed data was across systems and knew there had to be a better way to streamline data sharing across the industry. Later, during my time as chief patient safety officer at Stanford Health Care, I focused on improving the outcomes of patients through research and realized that healthcare lacked a real, scalable solution. That's when I turned to entrepreneurship alongside my co-founder, Sean O'Brien, an expert in software and regulated data, to help bring my vision to life—a national data layer that grants researchers and physicians access to the comprehensive and timely information they need to make more informed decisions without risking patient safety.' 'With the addition of these deep clinical measures, we're capturing healthcare outcomes at an unprecedented level of granularity,' he continued. 'This positions OMNY as the most comprehensive source of real-world clinical data in the U.S.—laying the foundation not just for patient-centered research, but for the next generation of healthcare analytics and AI-driven models.' OMNY Health's platform offers seamless integration with healthcare systems, enabling the aggregation of more than eight years of real-world clinical data. The data spans all 50 states, giving developers a truly national lens on care delivery trends, gaps, and outcomes. Crucially, OMNY provides filters and tooling that help AI developers target specific patient populations and clinical scenarios, reducing bias and improving model performance. It's a foundational layer for more responsible, inclusive AI development in healthcare. With over 4 billion clinical notes and rich metadata, OMNY's data trove unlocks insights buried deep in unstructured formats like physician dictations, discharge summaries, and imaging reports. This access is game-changing for AI startups and research teams, enabling faster training cycles, real-world validation, and broader scalability. OMNY isn't just selling data—it's fueling innovation. The company has partnered with leading AI-driven health tech firms such as QuantHealth, which focuses on AI-powered clinical trial simulations, and Atropos Health, a leader in generating personalized real-world evidence at the point and pace of care. These collaborations exemplify how OMNY's infrastructure can accelerate everything from drug development to care optimization. By bridging the gap between raw data and usable intelligence, OMNY is powering tools that predict patient outcomes, streamline documentation, and help researchers better understand treatment efficacy in diverse populations. 'As we see continued investment in AI solutions for healthcare, the technology's effectiveness is entirely dependent upon the quality of the data it's fed,' said Kevin Ryan, founder and CEO of AlleyCorp. 'By continuing to rapidly scale its network of real-world data, OMNY Health is building AI's essential foundation for success—a pivotal first step in paving the way for the innovation of safer and more equitable solutions that improve healthcare outcomes.' In late 2022, OMNY raised a $17 million Series B round to expand its platform and grow its network. The raise, led by existing and new strategic investors, signaled growing recognition of the company's role as a key enabler in AI health innovation. Unlike many data providers, OMNY focuses on longitudinal, de-identified data that supports both research and product deployment. Its regulatory and compliance framework makes it easy for customers to start building without navigating red tape or reinventing infrastructure. What makes OMNY's growth even more striking is how much it has achieved with relatively little capital. While peers like Truveta have raised more than $320 million to date, OMNY has scaled to a national footprint with a fraction of that funding, underscoring the capital efficiency of its model and the market's appetite for leaner, more flexible data solutions. OMNY Health presents various research findings from its extensive data network this week at ISPOR in Montreal. The conference, organized by the Professional Society for Health Economics and Outcomes Research, focuses on empowering data-driven, patient-centered decision-making that leads to more equitable, accessible, and effective healthcare solutions. OMNY's release of more than 300 new measures comes just weeks after its announcement of adding 4 billion unstructured notes—a move that unlocked troves of buried insights. With that historical depth and specialty coverage, OMNY is becoming more than a data company—it's a healthcare platform in disguise. Algorithms alone won't shape the future of medicine. It will be shaped by how well we can translate messy, fragmented health data into structured, accessible intelligence. OMNY's bet is clear: AI won't transform healthcare until we transform the data first. And if they're right, the most valuable tech companies in healthcare may not be the ones building the models, but the ones building the map. As AI rapidly reshapes the healthcare industry, the quality and equity of the underlying data will define who benefits—and who gets left behind. OMNY is betting that scale, diversity, and responsible data access will be the difference between AI that reinforces healthcare inequality and AI that helps fix it. With its strategy of building a transformative platform that prioritizes inclusivity and everyday impact, OMNY Health is emerging not just as a data vendor but as a foundational player in the future of medicine.
BBC News
08-05-2025
- Politics
- BBC News
Bereaved mother 'drained' by campaign to change social media law
A bereaved mother said she is feeling "emotionally drained" from her ongoing campaign calling for tech companies to hand over data after a person dies. Ellen Roome, from Cheltenham, Gloucestershire, has been fighting for a change in law since her 14-year-old son, Jools Sweeney, took his own life in April 2022. Ms Roome believes his death could have been linked to an online challenge gone amendment, called Jools' Law, would allow families to access user data from up to 12 months before the date of their loved one's Data (Use and Access) Bill was passed by MPs on Wednesday, but the change proposed by Ms Roome was not voted on. Some social media companies told Ms Roome that they cannot release the data because of issues around privacy. Others have said they would only do so if a court order was given. Although Ms Roome was left feeling "frustrated" by the outcome on Wednesday, she said a change allowing coroners to request the data from social media companies is a "positive" step, providing it definitely happens. Sir Chris Bryant, the Minister of State for Data Protection and Telecoms said the government will "do everything we possibly can" to ensure coroners understand their powers and duties outlined in the new added that he hopes tech companies embrace the change too and understand that they need to "look after" families who have lost loved ones. Ms Roome said that Jools' social media is the one thing that was not investigated after his death. "There was nothing offline when Jools died - there was no bullying, no mental health issues."We didn't look at a vital piece of evidence that could have given us answers." Later this month, she has a meeting with the Home Office and the Minister of Justice who is in charge of the coronial system to discuss the new bill. In the future, Ms Roome hopes that other grieving families will not be left in her situation. "I'm three years down the line with my 14-year-old child who's no longer here, with no answers to understand why on earth he did what he did and that's very frustrating. "I know of other parents going through the same situation right now and I look at them and think 'you are going to end up like me unless we change the system.' "That's where it's fundamentally wrong, in my opinion," she said.
